• Economy
  • Investing
Long Distance Investing
  • Stock
  • Editor’s Pick
Investing

CardioComm Solutions, Inc. Secures Exclusive Distribution Rights in Quebec for ECG Medical Devices

by August 29, 2024
written by August 29, 2024

Deal enhances access to long term continuous ECG monitoring devices for Canadians

August 28, 2024 6:04 PM EDT | Source: CardioComm Solutions, Inc.

Toronto, Ontario–(Newsfile Corp. – August 28, 2024) – CardioComm Solutions, Inc. (TSXV: EKG) (“CardioComm” or the “Company“), a global medical provider of consumer heart monitoring and medical electrocardiogram (“ECG”) software and hardware solutions, is pleased to announce an exclusivity agreement for the Province of Quebec for the sale and distribution of TZ Medical Inc. (“TZM”) ECG monitoring devices used for standard and extended Holter and cardiac arrhythmia monitoring.

CardioComm has had a long-standing relationship with the hardware manufacturer, Oregon-based TZM, and is a non-exclusive distributor for TZM’s ECG monitoring medical devices in Canada and the US. Of specific interest are the TZM Trident Pro and Trident Nano devices that are integrated with CardioComm’s class-leading Global Electrocardiogram Management software (GEMSTM), which is widely licensed by North American clinics and hospitals. The addition of Quebec exclusivity will facilitate hardware tendering processes with provincial hospitals that use or are considering a license for use of GEMSTM.

CardioComm will integrate the TZM Trident Pro and Nano devices with GEMSTM Holter and GEMS Long Term Continuous Monitoring (GEMS LTCM), two new CardioComm software releases planned for 2025. CardioComm’s GEMS LTCM will be positioned to meet the growing demand for combined, 14 to 30 day, Holter and Event monitoring. The new devices will join CardioComm’s growing product lines, including the HeartCheckTM branded home ECG devices, the Body-by-GEMSTM multiple bio-signal monitoring solutions, and the GEMSTM-based products for clinics and hospitals.

To learn more about CardioComm’s products and for further updates please visit the Company’s websites at www.cardiocommsolutions.com and www.theheartcheck.com.

About CardioComm Solutions

CardioComm Solutions’ patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 and ISO 27001 certifications, is HIPAA compliant and holds medical device clearances and sales licenses from the USA (FDA) and Canada (Health Canada).

Forward-looking statements

This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management’s current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/221458

SOURCE: CardioComm Solutions, Inc.

The post CardioComm Solutions, Inc. Secures Exclusive Distribution Rights in Quebec for ECG Medical Devices appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
BluMetric Announces Q3 2024 Financial Results
next post
Yangaroo Announces Q2’2024 Financial Results

You may also like

MEXC strengthens reserve backing with $390M asset increase

April 23, 2025

Oil prices rebound: what’s driving the rally and...

April 23, 2025

Silver rises with gold, but industrial demand outlook...

April 23, 2025

Lead Edge Capital founder Mitchell Green says recession...

April 23, 2025

Why is Toncoin price rising today?

April 23, 2025

BC.GAME to host ‘Untamed Arena’ during TOKEN2049 Dubai,...

April 23, 2025

Keycard launches pre-sale for Shell: the most open,...

April 23, 2025

BA stock rises as Boeing reports smaller Q1...

April 23, 2025

US stocks surge at open: Dow climbs 2.4%,...

April 23, 2025

iExec launches 1M $RLC fund to support AI...

April 23, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Cargo thieves are attacking the U.S. supply chain at alarming rates

      May 10, 2025
    • Krispy Kreme stock plunges after doughnut chain pauses McDonald’s rollout, pulls outlook

      May 8, 2025
    • UnitedHealthcare sued by shareholders over reaction to CEO’s killing

      May 8, 2025
    • Semtech Showcases Next-Gen LoRa® Technology at IoT Solutions World Congress 2025

      May 8, 2025

    Categories

    • Economy (680)
    • Editor's Pick (348)
    • Investing (4,555)
    • Stock (820)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: Longdistanceinvestings.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 Longdistanceinvestings.com

    Long Distance Investing
    • Economy
    • Investing
    Long Distance Investing
    • Stock
    • Editor’s Pick